CytoDyn Inc. is a clinical-stage biotechnology company focused on the development and potential commercialization of leronlimab (PRO 140), a humanized monoclonal antibody targeting the CCR5 receptor. The company's primary activities involve advancing leronlimab through clinical trials for solid-tumor oncology indications, including metastatic colorectal cancer and metastatic triple-negative breast cancer. CytoDyn is headquartered in Vancouver, Washington, and operates as a publicly traded entity dedicated to innovative therapeutic development.

CytoDyn generates revenue primarily through potential future product sales of leronlimab upon regulatory approval, as well as through license agreements, strategic partnerships, and non-dilutive financing opportunities. The company does not currently have commercial product sales, as leronlimab remains in clinical development. Revenue generation is tied to milestone payments, royalties, and potential co-development arrangements with partners in the biopharmaceutical sector.

The company operates through the following segments:

• Oncology: This segment focuses on the clinical development of leronlimab for solid-tumor cancers, including metastatic colorectal cancer and metastatic triple-negative breast cancer. The segment includes ongoing Phase II trials evaluating leronlimab in combination with standard-of-care therapies such as TAS-102 and bevacizumab for colorectal cancer, and carboplatin for breast cancer. Leronlimab is the proprietary product candidate under investigation in this segment.

• Long-Acting CCR5 Antagonist Development: This segment involves a joint development agreement with a third-party company utilizing generative AI drug discovery tools to create modified, longer-acting versions of leronlimab. The goal is to reduce injection frequency for patients and improve marketability through extended half-life formulations. This initiative remains in progress and aims to enhance the therapeutic profile of the CCR5 antagonist platform.

CytoDyn holds a niche position in the biotechnology industry as a developer of CCR5-targeted therapies, with leronlimab representing a differentiated approach due to its unique binding mechanism to the CCR5 receptor. The company competes with other immunotherapy and oncology-focused biotechs, though its specific mechanism—blocking calcium channel signaling rather than acting as an agonist—distinguishes it from other CCR5 antagonists. Competitive advantages include preclinical evidence suggesting potential effects on metastatic spread, tumor microenvironment modulation, and synergy with existing therapies like chemotherapy and immune checkpoint inhibitors.

CytoDyn serves patients with advanced solid tumors, particularly those with metastatic colorectal cancer and metastatic triple-negative breast cancer who have CCR5-positive tumors. The company also engages with clinical investigators, contract research organizations such as Syneos Health, and academic medical centers including Georgetown University/MedStar Health Alliance and Albert Einstein College of Medicine/Montefiore Medical Center for trial execution and research collaboration.